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Abstract Injection drug users (IDU) who use metham-
phetamine (MA) are at an increased risk of HIV infection
due to engagement in injection-related risk behavior
including syringe sharing. In this cohort study of young
IDU aged 18-30, we investigated the relationship between
injection MA use and syringe sharing, and whether difﬁ-
culty accessing sterile syringes mediated this association.
Behavioral questionnaires were completed by 384 IDU in
Vancouver, Canada between October 2005 and May 2008.
Generalized estimating equations were used to estimate
direct and indirect effects. The median age of participants
was 24 (IQR: 22–27) and 214 (55.7%) were male. Injecting
MA was independently associated with syringe sharing.
Mediation analyses revealed that difﬁculty accessing sterile
syringes partially mediated the association between
injecting MA and syringe sharing. Interventions to reduce
syringe sharing among young methamphetamine injectors
must address social and structural barriers to accessing HIV
prevention programs.
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Introduction
The sharing of non-sterile injecting equipment remains an
important risk factor for HIV acquisition and other blood-
borne diseases, despite impressive declines in injecting-
related risk behavior observed among injection drug users
(IDU) in several settings [1–3]. Substantial evidence exists
to suggest that needle and syringe exchange programs
(SEPs) have played an important role in reducing HIV risk
behavior and HIV seroconversion among IDU who use
these programs [4, 5]. However, recent studies have raised
concerns that a high prevalence of injection risk (including
receptive and distributive syringe sharing) persists among
new injectors and young IDU [6, 7]. Younger injectors are
less likely than adults to use SEPs, and those who do access
these services use them infrequently [8, 9]. Furthermore,
young IDU are less likely to return to SEPs after an initial
visit, with geographic proximity being a particularly
important predictor of retention [10]. Research that iden-
tiﬁes the evolving risk factors for syringe sharing among
young IDU and their barriers to accessing HIV prevention
programs is therefore required to inform more effective
interventions to reduce the risk of blood-borne disease
acquisition among this population.
The use of methamphetamine (MA) via injection among
adults has been associated with a variety of adverse health
and social consequences, including elevated rates of mor-
tality in some settings [11, 12]. Behavioral studies have
B. D. L. Marshall   E. Wood   T. L. Patterson   T. Kerr (&)
Urban Health Research Initiative, British Columbia Centre
for Excellence in HIV/AIDS, St. Paul’s Hospital, 608-1081
Burrard Street, Vancouver, BC V6Z 1Y6, Canada
e-mail: uhri-tk@cfenet.ubc.ca
B. D. L. Marshall   J. A. Shoveller
School of Population and Public Health, University of British
Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3,
Canada
E. Wood   T. Kerr
Department of Medicine, University of British Columbia,
St. Paul’s Hospital, 608-1081 Burrard Street, Vancouver,
BC V6Z 1Y6, Canada
T. L. Patterson
Department of Psychiatry, University of California,
9500 Gilman Drive, La Jolla, CA 92093-0680, USA
123
AIDS Behav (2011) 15:1546–1553
DOI 10.1007/s10461-010-9876-8also shown that adult MA injectors are more likely to
report sexual- and injection-related risk behavior compared
to other injectors [13–15]. Although much less research has
examined the health and behavioral consequences of MA
injection among youth, a recent systematic review con-
cluded that young MA injectors (compared to other drug
users) experience an increased risk of psychopathology and
drug-related harms including overdose [16].
The primary hypothesis of the present analysis was that
young people who inject MA would be more likely to report
syringe sharing as compared to young IDU who inject other
substances. Drawing on a growing literature demonstrating
that social and structural barriers to accessing SEPs are
important drivers of HIV risk behavior among IDU popu-
lations [17–19], we also hypothesized that reporting
difﬁculty accessing sterile syringes would mediate the
association between MA injection and syringe sharing.
These ﬁndings may inform the development of more effec-
tive behavioral and public health interventions aiming to
reduce syringe sharing and resultant infectious disease
transmission among young MA injecting populations.
Methods
Study Design
Data for these analyses were derived from three prospec-
tive cohort studies that compromise a larger program of
research examining the initiation and natural history of
injection drug use. All cohorts are based in Vancouver,
Canada and are operated by the British Columbia Centre
for Excellence in HIV/AIDS. Recruitment procedures from
each of the three cohorts are similar, with the primary
modes of enrolment being self-referral, street outreach, and
word of mouth. To be eligible for inclusion, all participants
must be living in the Greater Vancouver area, greater than
14 years of age at study entry, and provide informed
consent.
Although detailed sampling and recruitment procedures
have been published elsewhere [20–22], each study is
brieﬂy described here. The At Risk Youth Study (ARYS) is
a cohort of street-involved youth; thus, to be eligible,
participants must have been between the age of 14 and 26
at enrolment. All individuals must also had used illicit
drugs other than other in addition to marijuana in the past
30 days, with approximately 40% reporting a history of
injection drug use at their baseline visit [23]. The Van-
couver Injection Drug Users Study (VIDUS) is an open
prospective cohort of HIV-negative adult IDU. All VIDUS
participants must have injected an illicit drug in the past
6 months at the date of enrolment to be eligible for
inclusion. The AIDS Care Cohort to Evaluate Exposure to
Survival Services (ACCESS) is a cohort of HIV-positive
drug users, who, similar to those in ARYS, must have
recently used an illicit drug other than or in addition to
marijuana to be eligible to participate.
At baseline and semi-annually, participants complete a
detailed interviewer-administered questionnaire. The sur-
vey for ARYS, VIDUS, and ACCESS consists of a uniform
set of questions, which permits the aggregation of data
across all three cohorts. Study-speciﬁc information (e.g.,
injection drug use initiation in ARYS, HIV clinical care
experiences in ACCESS) are also collected but were not
used in this analysis. Nurses obtain blood specimens for
HIV and hepatitis C serology, provide basic medial ser-
vices, and offer referrals to appropriate health care services
including addiction treatment. All studies have been
approved by the University of British Columbia/Provi-
dence Health Care Research Ethics Board.
Participants
Data from all three cohorts were combined to achieve
sufﬁcient power to examine the predictors of syringe
sharing among young participants who reported active
injection drug use. All individuals who completed a base-
line survey between October 2005 and May 2008 were
eligible for inclusion. Thus, data used from each cohort
was collected during the same time frame. For this study,
individuals less than 30 years of age at enrolment were
eligible for inclusion. The sample was also restricted to
active IDU (i.e., participants who reported injecting at least
once in the 6 months prior to the baseline interview or one
of four follow-ups during the study period).
Measures
All variables examined in these analyses were assessed
consistently and equivalently across the three cohorts. The
dependent variable in this analysis was syringe sharing (yes
versus no), deﬁned as answering afﬁrmatively to either, ‘‘In
the past six months, have you ﬁxed with a rig that had
already been used by someone else?’’ or ‘‘In the past six
months, have you lent your used rig to someone else?’’ The
purchase or sale of syringes was not considered in the
outcome deﬁnition since in our instrument these events
refer explicitly to sterile products; therefore, the risk of
HIV transmission associated with this activity is low. The
primary independent variable of interest was injecting MA
(either alone or in combination with other drugs) at least
once in the 6 months prior to the interview (yes versus no).
The potential mediator assessed in this study was ‘‘difﬁ-
culty accessing sterile syringes’’, which was assessed by
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123examining responses to the question, ‘‘Do you ﬁnd it hard
to get new rigs when you need them?’’ Participants who
answered ‘‘yes’’ or ‘‘sometimes’’ were coded as having
difﬁculty accessing syringes versus those who reported
‘‘no’’.
The following covariates were assessed as potential
confounders: age (\24 versus C24), sex (male versus
female), ethnicity (Caucasian versus other), current rela-
tionship status (single/dating versus married/regular part-
ner), baseline HIV status (positive versus negative), and
homelessness (yes versus no). These variables have been
shown in previous studies to be important risk factors for
MA injection or syringe sharing [7, 13, 24–27] and thus
may confound the relationship between these two factors.
Finally, the number of years participants reported injecting,
non-injection MA use, crack use, injection cocaine use, and
injection heroin use were also examined in order to com-
pare the drug use patterns between MA injectors and non-
injectors.
Statistical Analysis
As a preliminary analysis, the characteristics of those who
did and did not report injecting MA at baseline were
compared using Pearson’s chi-square test for dichotomous
variables and the Kruskal–Wallis test for continuous vari-
ables. We then conducted a series of longitudinal analyses
to determine the independent association between MA
injection and syringe sharing over the study period. We
used a generalized estimating equation (GEE) approach
with logit link for binary outcomes since the factors asso-
ciated with syringe sharing, including the primary inde-
pendent variable of interest and many potential
confounders were serial (i.e., time-dependent) measures.
Since GEE account for the correlation between repeated
measures for each subject, valid estimates of association
and standard errors are obtained [28]. Furthermore, these
methods permitted the inclusion of all data collected in any
survey during which active injection drug use was reported
(i.e., participants did not need to report injecting drugs over
the entire study period to be eligible).
In order to identify potential confounders in the rela-
tionship between MA injection and syringe sharing, we
used an approach ﬁrst described by Hosmer and Lemeshow
[29]. We ﬁrst computed the estimate of association
between the outcome and the primary explanatory variable
of interest, and then assessed whether the addition of each
potentially confounding covariate resulted in a relative
change of this coefﬁcient by more than ±10%. All vari-
ables that achieved this a priori-deﬁned cut-off were con-
sidered confounders and thus included in all subsequent
regressions (see below).
As a next step, a mediation analysis was conducted
according to the procedures recommended by Baron and
Kenny [30]. Mediation analysis permits the examination of
potential mechanisms through which independent variables
(e.g., MA injection) impact health behaviors (e.g., syringe
sharing). Three multivariate longitudinal regressions were
conducted to determine the relationship between: (1) path
a, the independent variable (i.e., injecting MA) and the
mediator (i.e., difﬁculty accessing syringes); (2) path b, the
mediator and the dependent variable (i.e., syringe sharing),
adjusting for the effect of the independent variable; and (3)
path c, the independent variable and the dependent vari-
able. To determine the extent to which difﬁculty accessing
syringes mediated the association between injecting MA
and syringe sharing, a ﬁnal model with both the mediator
and independent variable as predictors of the dependent
variable was conducted to estimate coefﬁcient c0.I f
mediation is present, the magnitude and signiﬁcance of c0
should be less than c. In the case that the relationship is
explained entirely by the mediated pathway (i.e., full
mediation), c0 should equal zero. If the coefﬁcient remains
positive, partial mediation is present, which indicates that
although the mediator may be important, it does not fully
account for the relationship between the dependent and
independent variables. Finally, to determine the statistical
signiﬁcance of the proposed mediation pathway, a Sobel
test was conducted [31]. This test is used to determine
whether the indirect effect of the independent variable on
the dependent variable via the mediator is signiﬁcantly
different from zero.
We recognized that the primary exposure (i.e., any MA
injection in the past 6 months) was very broadly deﬁned,
and as such may not represent individuals who primarily or
very frequently inject MA. Therefore, as a sensitivity
analysis, we examined whether a more stringently-deﬁned
independent variable also predicted higher rates of syringe
sharing and difﬁculty accessing sterile syringes. The
mediation analyses described above were thus repeated,
using as a primary explanatory variable frequent (i.e., at
least daily) versus non-frequent (i.e., less than daily) MA
injection in the past 6 months. All statistical analyses were
conducted using SAS version 9.1.3 (SAS Institute Inc.,
Cary, NC) and all P-values are two-sided.
Results
Descriptive Statistics
Among 756 young participants recruited, 384 (50.8%)
reported injecting over the study period and were thus
eligible for inclusion in this analysis. The median age of
eligible respondents was 24.2 [interquartile range (IQR):
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12322.0–26.8], 214 (55.7%) were male, and 244 (63.5%) were
of Caucasian ethnicity. At baseline, 187 (48.7%) reported
injecting MA at least once in the past 6 months; of these,
56 (30.0%) reported doing as at least daily. The median
number of years participants reported injecting was 7 (IQR:
4–10). Other sociodemographic, behavioral, and drug use
information stratiﬁed by baseline self-reported MA injec-
tion is reported in Table 1.
Bivariate Analyses
Several signiﬁcant differences between MA injectors and
non-MA injectors were observed. The former group
reported signiﬁcantly fewer years injecting: six versus
eight, respectively (v
2 = 11.0, df = 1, P = 0.001). As
shown in Table 1, MA injectors were more likely to be less
than 24 years of age (53.8 vs. 41.4%, P = 0.016), male
Table 1 Baseline characteristics of young IDU, stratiﬁed by self-reported methamphetamine (MA) injection (n = 384)
Characteristic Inject MA
a
(n = 187) (N,% )
Did not inject MA
a
(n = 197) (N,% )
OR (95% CI) P-value
Age
\24 99 (53.8) 79 (41.4) 1.64 (1.10–2.50) 0.016
C24 85 (46.2) 112 (58.6)
Sex
Male 116 (62.7) 98 (51.0) 1.61 (1.06–2.44) 0.023
Female 69 (37.3) 94 (49.0)
Ethnicity
Caucasian 133 (71.9) 111 (57.8) 1.87 (1.21–2.87) 0.004
Other 52 (28.1) 81 (42.2)
Relationship status
Single/dating 142 (75.9) 126 (65.0) 1.70 (1.09–2.66) 0.020
Married/regular partner 45 (24.1) 68 (35.0)
HIV status
Positive 20 (10.8) 29 (15.1) 0.68 (0.37–1.25) 0.217
Negative 165 (89.2) 163 (84.9)
Homeless
a
Yes 119 (63.6) 114 (57.9) 1.27 (0.84–1.92) 0.247
No 68 (36.4) 83 (55.0)
Non-injection MA use
a
Yes 110 (59.5) 22 (11.2) 11.60 (6.81–19.74) \0.001
No 75 (40.5) 174 (88.8)
Crack use
a
Yes 126 (67.4) 151 (77.0) 0.62 (0.39–0.97) 0.035
No 61 (32.6) 45 (23.0)
Injection cocaine use
a
Yes 56 (30.6) 82 (42.3) 0.60 (0.39–0.92) 0.019
No 127 (69.4) 112 (57.7)
Injection heroin use
a
Yes 111 (61.3) 157 (80.1) 0.39 (0.25–0.63) \0.001
No 70 (38.7) 39 (19.9)
Syringe sharing
a
Yes 47 (25.3) 29 (14.7) 1.96 (1.17–3.28) 0.010
No 139 (74.7) 168 (85.3)
Difﬁculty accessing syringes
a
Yes 89 (50.9) 56 (30.9) 2.31 (1.50–3.56) 0.008
No 86 (49.1) 125 (69.1)
Note: Not all cells add to 100% due to missing values
a During the 6 months prior to the date of the ﬁrst interview during which injection drug use was reported over the study period
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123(62.7 vs. 51.0%, P = 0.023), Caucasian (71.9 vs. 57.8%,
P = 0.004), and single or casually dating (75.9 vs. 65.0%,
P = 0.020). Drug use patterns also varied signiﬁcantly
between the two groups, with MA injectors more likely to
report non-injection MA use (59.5 vs. 11.2%, P\0.001),
but less likely to report crack use, injection cocaine use,
and injection heroin use (see Table 1). At baseline, syringe
sharing (25.3 vs. 14.7%, P = 0.010) and having difﬁculty
accessing sterile syringes (50.9 vs. 30.9%, P = 0.008)
were signiﬁcantly more common among participants who
injected MA.
Longitudinal and Mediation Analyses
The results of the mediation analyses are shown in Fig. 1.
In longitudinal analysis, MA injection was found to be
signiﬁcantly associated with syringe sharing [c = 0.49,
odds ratio (OR) = 1.63, P = 0.017]. In a series of GEE
models examining the effect of potential confounders, only
relationship status was found to change the estimate
between MA injection and syringe sharing by greater than
±10% [relative change =? 10.2%, c = 0.54, adjusted
odds ratio (AOR) = 1.73, P = 0.008]. Thus, relationship
status was controlled for in all subsequent regressions. As
shown in Fig. 1, MA injectors were more likely to report
having difﬁculty accessing syringes (a = 0.89, AOR =
2.43, P\0.001). When MA injection and relationship
status were controlled for, difﬁculty accessing syringes was
positively associated with syringe sharing (b = 0.45,
AOR = 1.56, P = 0.026). After controlling for difﬁculty
accessing syringes, the coefﬁcient for MA injection lost
signiﬁcance and decreased in magnitude (c0 = 0.40,
AOR = 1.49, P = 0.067), indicating partial mediation.
A Sobel test to examine the indirect effect of difﬁculty
accessing syringes on the relationship between injecting
MA and syringe sharing conﬁrmed the signiﬁcance of the
mediation pathway (P = 0.040).
A sensitivity analysis demonstrated that frequent (i.e., at
least daily) MA injectors were signiﬁcantly more likely to
report syringe sharing (AOR = 2.60, P\0.001) and dif-
ﬁculty accessing sterile syringes (AOR = 2.19, P\0.001)
over the study period. Consistent with the results of the
primary analysis, having difﬁculty accessing syringes par-
tially mediated the association between frequent MA
injection and syringe sharing (Sobel test P-value = 0.053).
Discussion
Consistent with previous studies [13, 15, 32], we observed
a positive and signiﬁcant association between MA injection
and syringe sharing among a cohort of young injection
drug users. Furthermore, participants who injected MA
were over twice as likely to report having difﬁculty
accessing sterile syringes compared to other active IDU. In
a series of longitudinal regression analyses, the relationship
between MA injection and syringe sharing was shown to be
partially mediated by difﬁculty accessing syringes. These
results suggest that the high prevalence of injecting-related
risk behavior observed among young IDU may be driven
by ongoing social and structural barriers to accessing HIV
prevention programs, and that MA injectors experience
particularly elevated exposure to infectious disease risk.
Previous studies have demonstrated that reporting dif-
ﬁculty accessing sterile syringes has historically been one
of the primary risk factors for syringe sharing, even in the
presence of well-established syringe exchange programmes
[17, 33]. In Vancouver, programmatic barriers, including
limited hours of operation, restrictive (i.e., one-for-one)
exchange policies, and travel distance are among the most
common reasons for having difﬁculty accessing these ser-
vices [33, 34]. In response to these concerns, the local
health authority began a series of SEP policy reforms in
2000, including: a shift to syringe distribution and recovery
instead of one-for-one exchange; decentralizing services to
expand the number of sites distributing supplies; and
diversifying the delivery of these services to include ﬁxed-
site programs, outreach, foot patrols, peer-run programs,
and the distribution of supplies at all local health clinics
and pharmacies. These policy changes have recently been
shown to have resulted in large reductions in syringe
sharing among IDU and have contributed to declining HIV
incidence [1].
Our results suggest that young MA injectors continue
to report having difﬁculty accessing sterile syringes, even
in an era of high coverage, widespread syringe distribution.
Further research will be required to determine the most
common individual, social, and structural barriers
Fig. 1 Mediation analysis of the direct and indirect effects of
injection methamphetamine (MA) use on syringe sharing among
young IDU (n = 384). Note: All models are adjusted for relationship
status
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123experienced by young people who inject MA, although
existing studies suggest that some of the factors previously
reported by adult IDU continue to affect this population’s
access to HIV prevention interventions [8, 10]. For
example, since geographic proximity to SEPs is an
important predictor of programme utilization and risk
behavior [34, 35], it is possible that many MA injectors
either are not in close proximity to SEPs or avoid areas
where they are located. Ethnographic work in our setting
has shown how youth perceive neighbourhoods with
extensive open drug scenes (and thus a concentration of
SEPs) as being environments of exceptional danger and
actively seek to avoid it [36]. Furthermore, MA injectors
may feel uncomfortable or unwelcome accessing HIV
prevention programs that cater largely to opioid users [37].
For these reasons, future SEP expansion and development
should consider the perspectives of young MA injectors to
determine how these programmes can be accessed more
safely, including for example locating services in areas
frequented by young MA-using IDU and adopting peer-
based stafﬁng models.
While structural barriers clearly contribute to ones’ (in)-
ability to access HIV prevention services, other individual
factors and social inﬂuences may be operating to prevent
MA injectors from obtaining sterile syringes. For example,
MA users may have difﬁculty accessing safer injecting
equipment while on multi-day drug ‘‘binges’’ or during
periods of MA-induced psychological distress [38]. Prior
research has also shown that MA injectors (compared to
heroin users) are more likely to inject in groups or with
friends, which may promote the sharing of syringes and
other injecting equipment [39]. Future research will be
required to identify at what level barriers to service access
are operating, and how individual, social, and structural
barriers intersect to produce HIV-related harms.
The results of this study have a number of important
implications for future interventions that seek to address
injection-related risk behavior among young MA injectors.
Given that MA users are more likely to experience barriers
while attempting to access harm reduction and HIV pre-
vention services, interventions and policies that promote
secondary syringe distribution (i.e., receiving supplies from
peers who access SEPs) are recommended. Youth-driven
models of syringe distribution, including ﬁxed and out-
reach-based services run by or catered speciﬁcally to youth,
have also been shown to be successful in numerous settings
[40, 41]. Given the effectiveness of supervised injecting
facilities (SIFs) at reducing syringe sharing among hard-to-
reach and hidden populations [26], the development of
youth-friendly SIFs that are acceptable to individuals
injecting MA should also be considered. Furthermore,
interventions that harness social inﬂuence and promote
positive peer norms among MA-using IDU networks may
be effective at reducing risk behavior and encouraging
uptake of HIV prevention and other health services [42].
Efforts must be made to develop effective HIV prevention
strategies tailored speciﬁcally to MA injectors, given the
unique injecting practices and health issues experienced by
this population [43]. Finally, future research in this area
may beneﬁt from the incorporation of novel methodologies
[including for example geographic information systems
(GIS)] to determine the geographic distribution and cov-
erage of services that would most effectively meet the
needs of this vulnerable IDU subpopulation. For example, a
recent study in New York City used GIS methodology to
demonstrate substantial cross-neighbourhood variation in
SEP access [44], although it remains to be determined
whether speciﬁc subgroups of injectors (including young
IDU and MA users) are disproportionately affected by the
inequitable geographic distribution of services in this
setting.
When drawing conclusions from this study, several lim-
itations should be noted. The ARYS, VIDUS, and ACCESS
cohorts are not random samples of the populations they seek
to represent; therefore, generalizability to the larger drug-
using community or other settings may be limited. We note
however that the sociodemographic characteristics of these
samples are similar to other street youth and injection drug-
usingstudiesthathavebeenconductedinCanada[45,46].A
second limitation is that all behaviors assessed in this study
were self-reported, and it is possible that stigmatized
behaviors including syringe sharing may have been under-
reported. However, we have no reason to believe the mag-
nitude of this bias would differ between MA injectors and
non-injectors; therefore, if present, socially desirable
reporting would attenuate our results towards the null. We
note also that previous studies have shown young peoples’
self-reportstobereliablemeasuresofdruguseandotherHIV
risk behaviors [47, 48]. Finally, although the statistical
methods usedintheseanalysesprecludeinferenceregarding
causality,thelongitudinalnatureoftheanalysissuggeststhat
the observed relationships were stable over time. Longer-
term studies are required to determine whether improve-
ments in syringe access mitigate injection risk behaviors
among young people who inject MA.
YoungMA injectors continue tobeatanincreasedriskof
syringe sharing, even in the presence of well-established,
high coverage syringe distribution programmes. A series of
meditational analyses revealed that having difﬁculty access-
ing sterile syringes is frequently reported by young MA-
using IDU, and that these barriers largely accounted for the
relationship between injecting MA and syringe sharing.
Novel,youth-driveninterventions,includingtheexpansionof
current services to adequately meet the needs of this popula-
tion, are required to reduce blood-borne disease transmission
among young people who inject methamphetamine.
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